Corcept Therapeutics Inc (CORT)
22.71
+0.50
(+2.25%)
USD |
NASDAQ |
Apr 26, 12:35
Corcept Therapeutics Revenue (Quarterly): 135.40M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 135.40M |
| September 30, 2023 | 123.60M |
| June 30, 2023 | 117.72M |
| March 31, 2023 | 105.65M |
| December 31, 2022 | 103.06M |
| September 30, 2022 | 101.73M |
| June 30, 2022 | 103.39M |
| March 31, 2022 | 93.69M |
| December 31, 2021 | 98.82M |
| September 30, 2021 | 96.13M |
| June 30, 2021 | 91.59M |
| March 31, 2021 | 79.44M |
| December 31, 2020 | 85.74M |
| September 30, 2020 | 86.33M |
| June 30, 2020 | 88.56M |
| March 31, 2020 | 93.25M |
| December 31, 2019 | 87.90M |
| September 30, 2019 | 81.50M |
| June 30, 2019 | 72.26M |
| March 31, 2019 | 64.83M |
| December 31, 2018 | 66.83M |
| September 30, 2018 | 64.44M |
| June 30, 2018 | 62.31M |
| March 31, 2018 | 57.66M |
| December 31, 2017 | 53.28M |
| Date | Value |
|---|---|
| September 30, 2017 | 42.76M |
| June 30, 2017 | 35.56M |
| March 31, 2017 | 27.60M |
| December 31, 2016 | 23.81M |
| September 30, 2016 | 21.72M |
| June 30, 2016 | 19.72M |
| March 31, 2016 | 16.06M |
| December 31, 2015 | 14.97M |
| September 30, 2015 | 13.26M |
| June 30, 2015 | 11.96M |
| March 31, 2015 | 10.10M |
| December 31, 2014 | 9.014M |
| September 30, 2014 | 7.282M |
| June 30, 2014 | 5.851M |
| March 31, 2014 | 4.405M |
| December 31, 2013 | 4.115M |
| September 30, 2013 | 2.634M |
| June 30, 2013 | 1.891M |
| March 31, 2013 | 1.717M |
| December 31, 2012 | 1.377M |
| September 30, 2012 | 1.055M |
| June 30, 2012 | 0.875M |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
72.26M
Minimum
Jun 2019
135.40M
Maximum
Dec 2023
97.14M
Average
93.69M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Ultragenyx Pharmaceutical Inc | 127.39M |
| Alnylam Pharmaceuticals Inc | 439.72M |
| Catalyst Pharmaceuticals Inc | 110.57M |
| United Therapeutics Corp | 614.70M |
| XOMA Corp | 1.833M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 31.36M |
| Total Expenses (Quarterly) | 103.74M |
| EPS Diluted (Quarterly) | 0.28 |
| Enterprise Value | 1.931B |
| Gross Profit Margin (Quarterly) | 98.61% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | 4.18% |
| Operating Earnings Yield | 4.23% |
| Normalized Earnings Yield | 4.183 |